Global private investment firm Bridgewest Group has announced the signing of a definitive agreement to purchase the sterile injectable manufacturing facility of Pfizer (Perth) Pty, a subsidiary of Pfizer, Inc.
The cGMP manufacturing facility, located in Bentley, a Perth suburb in Western Australia, is a diverse sterile injectable manufacturing facility, approved to supply drug products in over 90 countries globally with approvals secured by regulatory bodies including the FDA, TGA, EU and others. The facility has extensive blow fill seal (BFS) capabilities for producing sterile injectable essential drug products as well as significant capabilities to produce specialty oncology drug products for global distribution. In addition to the operations and facility, Bridgewest Group will also be acquiring a suite of drug products from Pfizer which it will look to aggressively market and expand globally.
The Perth operation will be a separate and distinct business from BioCina. "We are confident that the experience and expertise garnered with BioCina will translate to a smooth transition followed by substantial growth, as well as further cement Bridgewest Group's commitment to pharma manufacturing in Australia," said Dr. Masood Tayebi, Co-Founder and Chief Executive Officer of Bridgewest Group.
